Phio Pharmaceuticals appoints Robert Bitterman as interim Executive Chairman, effective Sept. 26, 2022

Phio Pharmaceuticals Corp.

Robert Bitterman, Board Chairman since 2012, named interim Executive Chairman and principal executive/financial officer.
Bitterman receives $175,000 annual base salary (incl. $55,000 Board fee) and 40,000 RSUs vesting Oct. 1, 2023.
Dr. Geert Cauwenbergh ceases as interim principal executive/financial officer and resumes independent Board role.
Robert Ferrara appointed Lead Independent Director; he chairs the Audit Committee and is a CPA.
Press release issued Sept. 29, 2022, announcing the leadership changes.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Geert Cauwenbergh

Independent Director

PHIO · Phio Pharmaceuticals Corp.

Effective: 2022-09-26
Filed: September 29, 2022, 7:59 PM ET

Dr. Geert Cauwenbergh, a member of the Company’s Board, will no longer serve as the Company’s interim principal executive officer and interim principal financial officer, which positions he held since May 4, 2022.

Appointed (interim)

Robert J. Bitterman

Interim Executive Chairman

PHIO · Phio Pharmaceuticals Corp.

Effective: 2022-09-26
Filed: September 29, 2022, 7:59 PM ET

approved the appointment of Robert J. Bitterman, Chairman of the Company’s Board, to serve as the Company’s interim Executive Chairman, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Geert Cauwenbergh changed role as Independent Director at Phio Pharmaceuticals Corp..

Action: ceased serving as interim PEO/PFO and resumed independent director role
Role: Independent Director

Exact text from the filing

Dr. Geert Cauwenbergh, a member of the Company’s Board, will no longer serve as the Company’s interim principal executive officer and interim principal financial officer, which positions he held since May 4, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Robert J. Bitterman was appointed as Interim Executive Chairman at Phio Pharmaceuticals Corp..

Action: appointed
Role: Interim Executive Chairman

Exact text from the filing

approved the appointment of Robert J. Bitterman, Chairman of the Company’s Board, to serve as the Company’s interim Executive Chairman, effective immediately.

View on SEC.gov

Phio Pharmaceuticals Corp. filing history →

Source: SEC EDGAR

accession 0001683168-22-006665

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.